News Updates
More Articles
- Pfizer touts safety of Omicron-targeting COVID-19 dose
- EMA backs conditional approval for hemophilia gene therapy
- CAR T cell candidate BNT211 granted PRIME designation
- Two COVID-19 tests from Euroimmun receive CE marks
- Sanofi, Health2Sync to partner for digital diabetes management
Pfizer touts safety of Omicron-targeting COVID-19 dose
Adjustments made by Pfizer and partner BioNTech to their COVID-19 vaccine were found to be safe and made the shot more effective at targeting the Omicron variant, Pfizer announced. Though the existing vaccines remain effective at protecting against severe COVID-19, they targeted the original coronavirus strain and have weakened against the very transmissible Omicron variant. The Associated Press (6/25)
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!